甲状腺癌的基因治疗

程刚

甲状腺癌的基因治疗

程刚

文章导航 > 国际放射医学核医学杂志 > 2002, 26 > 6: (253-256)

引用本文:

Citation:

甲状腺癌的基因治疗

程刚

400016 重庆, 重庆医科大学附一院核医学科

作者简介: 程刚(1973-),男,硕士研究生,住院医师,主要从事甲状腺疾病的研究。;

中图分类号: R736.1;R817.5

Gene therapy for thyroid cancer

CHENG Gang

Department of Nuclear Medicine, the First Hospital Affiliated to Chongqing University of Medical Sciences, Chongqing 400016, China
CLC number: R736.1;R817.5

摘要: 甲状腺癌的基因治疗包括免疫基因疗法,自杀基因疗法,抑癌基因疗法,NIS基因介导的¹³¹I治疗,反义基因治疗等,具有广阔的前景,但应用于临床还有许多的问题需要解决。
- 甲状腺癌 /
- 基因治疗 /
- 放射性碘
Abstract: Gene therapy for thyroid cancer include immunotherapy,suicide gene therapy,tumor suppressor replacement,¹³¹I therapy by sodium/iodide symporter and antisense therapy and so on.Gene therapy has wide perspectives,but there are many problems need to be solved for clinical application.
- thyroid cancer /
- gene therapy /
- radioiodine
本作品遵循Signature-Non-Commercial Use 4.0 International (CC BY-NC 4.0)协议

[1]	Zhang R, Baunoch D, De Groot LJ. Genetic immunotherapy for medullary thyroid carcinoma:destruction of tumors in mice by in vivo delivery of adenoviral vector transducing the murineinterleukin-2 gene[J]. Thyroid, 1998, 8(12):1137-1146.
[2]	Zhang R, Straus FH, De Groot LJ. Effective genetic therapy of established medullary thyroid carcinomas with murine interleukin-2:dissemination and cytotoxicity studies in a rat tumor model[J]. Endocrinology, 1999, 140(5):2152-2158.
[3]	Zhang R, De Groot LJ. Genetic immunotherapy of established tumours with adenoviral vectors transducing murine interleukin-12(mIL12) subunits in a rat medullary thyroid carcinoma model[J]. Clin Endocrinol (Oxt), 2000, 52(6):687-694.
[4]	Yamazaki M, Zhang R, Straus FH, et al. Effective gene therapy for medullary thyroid carcinoma using recombinant adenovirus inducing tumor-specific expression of interleukin-12[J]. Gene Ther, 2002, 9(1):64-74.
[5]	Soler MN, Bobe P, Benihoud K, et al. Gene therapy of rat medullary thyroid cancer by naked nitric oxide synthase Ⅱ DNA injection[J]. J Gene Med, 2000, 2(5):344-352.
[6]	Nishihara E, Nagayama Y, Mawatari F, et al. Retrovirusmediated herpes simplex virus thymidine kinase gene transduction renders human thyroid carcinoma cell lines sensitive to ganciclovir and radiation in vitro and in vivo[J]. Endocrinology, 1997, 138(11):4577-4583.
[7]	Braiden V, Nagayama Y, Iitaka M, et al. Retroviras-mediated suicide gene/prodrug therapy targeting thyroid carcinoma using a thyroid-specific promoter[J]. Endocrinology, 1998, 139(9):3996-3999.
[8]	Nagayama Y, Nishihara E, Iitaka M, et al. Enhanced efficacy of transcriptionally targeted suicide gene/prodrug therapy for thyroid carcinoma with the Cre-loxP system[J]. Cancer Res, 1999, 59(13):3049-3052.
[9]	Shimura H, Suzuki H, Miyazaki A, et al. Transcriptional activation of the thyroglobulin promoter directing suicide gene expression by thyroid transcription factor-1 in thyroid cancer cells[J]. Cancer Res, 2001, 61(9):3640-3646.
[10]	Kitazono M, Chuman Y, Aikou T, et al. Adenovirus HSVTK construct with thyroid-specific promoter:Enhancement of activity and specificity with histone deacetylase inhibitors and agents modulating the camp pathway[J]. Int J Cancer, 2002, 99(3):453-459.
[11]	Zhang R, De Groot LJ. Gene therapy of established medullary thyroid carcinoma with herpes simplex viral thymidine kinase in a rat tumor model:relationship of bystander effect and antitumor efficacy[J]. Thyroid, 2000, 10(4):313-319.
[12]	Zhang R, De Groot LJ. An adenoviral vector expressing functional heterogeneous proteins herpes simplex viral thymidine kinase and human interleukin-2 has enhanced in vivo antitumor activity against medullary thyroid carcinoma[J]. Endocr Relat Cancer, 2001, 8(4):315-325.
[13]	Narimatsu M, Nagayama Y, Akino K, et al. Therapeutic usefulness of wild-type p53 gene introduction in a p53-null anaplastic thyroid carcinoma cell line[J]. J Clin Endocrinol Metab, 1998, 83(10):3668-3672.
[14]	Kim SB, Ahn IM, Park HI, et al. Growth inhibition and chemosensitivity of poorly differentiated human thyroid cancer cell line (NPA) transfected with p53 gene[J]. Head Neck, 2001, 23(3):223-229.
[15]	Nagayama Y, Shigematsu K, Namba H, et al. Inhibition of angiogenesis and tumorigenesis, and induction of dormancy by p53 in a p53-null thyroid carcinoma cell line in vivo[J]. Anticancer Res, 2000, 20(4):2723-2728.
[16]	Nikitin AY, Juarez-Percz MI, Li S, et al. Rb-mediated suppression of spontaneous multiple neuroendocrine neoplasia and lung metastases in Rb^+/-mice[J]. Proc Natl Acad Sci USA, 1999, 96:3916-3921.
[17]	Moretti F, Nanni S, Farsetti A, et al. Effects of exogenous p53 transduction in thyroid tumor cells with different p53 status[J]. J Clin Endocrinol Metab, 2000, 85(1):302-308.
[18]	Caillou B, Troalen F, Baudin E, et al. Na⁺/I^- symporter distribution in human thyroid tissues:an immunohistochemical study[J]. J Clin Endocrinol Metab, 1998, 83(11):4102-4106.
[19]	Kitazono M, Robey R, Zhan Z, et al. Low concentrations of the histone deacetylase inhibitor, depsipepfide(FR901228), increase expression of the Na(+)/I(-) symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells[J]. J Clin Endocrinol Metab, 2001, 86(7):3430-3435.
[20]	Cerutti J, Trapasso F, Battaglia C, et al. Block of c-myc expression by anfisense oligonucleotides inhibits proliferation of human thyroid carcinoma cell lines[J]. Clin Cancer Res, 1996, 2:119-126.
[21]	Hanpt K, Siegel F, Lu M, et al. Induction of a cellular and humoral immune response against the tumor associated antigen calcitonin by genetic immunization[J]. J Endocrinol Invest, 1999, 22(suppl):4.
[22]	Schmutzler C, Koehrle J. Innovative strategies for the treatment of thyroid cancer[J]. Eur J Endocrinol, 2000, 143(1):15-24.
[23]	De Groot LJ, Zhang R. Clinical review 131-:Gene therapy for thyroid cancer:where do we stand?[J]. J Clin Endocrinol Metab, 2001, 86(7):2923-2928.

[1]	张一帆 , 李彪 . 钠/碘同向转运体在甲状腺癌¹³¹I治疗中的应用. 国际放射医学核医学杂志, 2004, 28(6): 249-252.
[2]	唐忠群 . ¹³¹I治疗非毒性多发结节性甲状腺肿. 国际放射医学核医学杂志, 2000, 24(3): 120-121.
[3]	夏劲松 . 放射技术与基因治疗. 国际放射医学核医学杂志, 2001, 25(3): 138-141.
[4]	陈立波 . 钠/碘同向转运体与放射性碘治疗. 国际放射医学核医学杂志, 2001, 25(6): 258-261.
[5]	宋进华 . 乳腺癌的基因治疗与核素靶向治疗. 国际放射医学核医学杂志, 2003, 27(6): 241-244.
[6]	余永利 . 不摄取¹³¹I的甲状腺癌治疗. 国际放射医学核医学杂志, 2005, 29(2): 57-63.
[7]	郑爱青 , 于金明 . 对乏氧和射线应答的嵌合性基因启动子的研究进展. 国际放射医学核医学杂志, 2004, 28(2): 74-77.
[8]	朱昌寿 . 放射性碘的危害评价. 国际放射医学核医学杂志, 1995, 19(4): 172-176.
[9]	穆传杰 , 周继文 . 报告基因显像监测基因治疗研究进展. 国际放射医学核医学杂志, 2003, 27(1): 4-8.
[10]	穆传杰 . 肿瘤基因治疗中的基因显像. 国际放射医学核医学杂志, 1999, 23(3): 128-131.